Canaccord Genuity on CleanTech/Bioresources: The Revolution in Renewable Chemicals
Tweet
Share
E-mailGet Alerts GEVO Hot Sheet
Price: $1.54 +1.99%
Rating Summary:
10 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
10 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity on CleanTech/Bioresources: The Revolution in Renewable Chemicals
Analyst, John Quealy, said, "Our thesis behind the emergence of renewable chemicals is straightforward: reducing dependence on volatile and geographically dispersed crude oil supplies, addressing large and growing markets with new (and potentially more environmentally friendly) products, and monetizing rapid technology advancements in the areas of biotechnology and synthetic biology (manipulating DNA to create desired results)."
"The emerging (though still nascent) bio-based chemicals and materials market addresses diverse petrochemical-based markets, representing myriad commercial endproducts. Price spread versus alternatives is critical, with the ultimate goal being able to make the same chemicals currently derived from oil and gas from renewable resources and at cheaper cost. Similar to biotechnology, risks should be considered elevated for this speculative and emerging marketplace, as commercialization hurdles are formidable."
Canaccord initiates coverage on Gevo (Nasdaq: GEVO) with a Buy and $16 price target: "We expect Gevo’s pioneering technology to successfully ramp into commercial production of cost-effective gateway chemicals, such as isobutanol, over the next 12 months."
Canaccord initiates coverage on Solazyme (Nasdaq: SZYM) with a Buy and $19 price target: "We believe the company’s unique technology platform and end-product diversity position it well to continue to be a leader in the attractive renewable oil and chemicals marketplace."
Analyst, John Quealy, said, "Our thesis behind the emergence of renewable chemicals is straightforward: reducing dependence on volatile and geographically dispersed crude oil supplies, addressing large and growing markets with new (and potentially more environmentally friendly) products, and monetizing rapid technology advancements in the areas of biotechnology and synthetic biology (manipulating DNA to create desired results)."
"The emerging (though still nascent) bio-based chemicals and materials market addresses diverse petrochemical-based markets, representing myriad commercial endproducts. Price spread versus alternatives is critical, with the ultimate goal being able to make the same chemicals currently derived from oil and gas from renewable resources and at cheaper cost. Similar to biotechnology, risks should be considered elevated for this speculative and emerging marketplace, as commercialization hurdles are formidable."
Canaccord initiates coverage on Gevo (Nasdaq: GEVO) with a Buy and $16 price target: "We expect Gevo’s pioneering technology to successfully ramp into commercial production of cost-effective gateway chemicals, such as isobutanol, over the next 12 months."
Canaccord initiates coverage on Solazyme (Nasdaq: SZYM) with a Buy and $19 price target: "We believe the company’s unique technology platform and end-product diversity position it well to continue to be a leader in the attractive renewable oil and chemicals marketplace."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- DA Davidson Starts Everus (ECG) at Buy
- Beike (BEKE) PT Raised to $23 at Morgan Stanley
Create E-mail Alert Related Categories
Analyst Comments, New CoverageRelated Entities
Crude OilSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
